Interactions between Bricanyl and Granisetron

Granisetron has a moderate potential interaction with Arrhythmia.

The IV and oral formulations of granisetron should be used with caution in patients with preexisting arrhythmias or cardiac conduction disorders because QT prolongation has been reported. Patients with cardiac disease, electrolyte abnormalities, cardiotoxic chemotherapy, or concomitant QT-prolonging drugs may be particularly at risk for clinical consequences.

Granisetron has a moderate potential interaction with Cardiovascular Conditions and Disorders.

The IV and oral formulations of granisetron should be used with caution in patients with preexisting arrhythmias or cardiac conduction disorders because QT prolongation has been reported. Patients with cardiac disease, electrolyte abnormalities, cardiotoxic chemotherapy, or concomitant QT-prolonging drugs may be particularly at risk for clinical consequences.

Granisetron has a moderate potential interaction with Constipation.

Granisetron may mask a progressive ileus and/or gastric distention. Monitor for decreased bowel activity, particularly in patients with risk factors for gastrointestinal obstruction or following recent abdominal surgery. In patients with preexisting constipation receiving subcutaneous granisetron, consider optimizing bowel regimens.

The terbutaline in Bricanyl has a moderate potential interaction with Diabetes Mellitus.

Adrenergic bronchodilators may cause increases in blood glucose concentrations. These effects are usually transient and slight, but may be significant with dosages higher than those normally recommended. Large doses of IV albuterol (not commercially available in the U.S.) and terbutaline sulfate have been reported to cause exacerbation of preexisting diabetes mellitus and ketoacidosis. Therapy with adrenergic bronchodilators should be administered cautiously in patients with diabetes mellitus. Closer monitoring of blood glucose concentrations may be appropriate. Systemic adverse effects are minimized, but not abolished, by administration of these agents via oral inhalation.

Granisetron has a moderate potential interaction with Electrolyte Abnormalities.

The IV and oral formulations of granisetron should be used with caution in patients with preexisting arrhythmias or cardiac conduction disorders because QT prolongation has been reported. Patients with cardiac disease, electrolyte abnormalities, cardiotoxic chemotherapy, or concomitant QT-prolonging drugs may be particularly at risk for clinical consequences.

Granisetron has a moderate potential interaction with Gastrointestinal Obstruction.

Granisetron may mask a progressive ileus and/or gastric distention. Monitor for decreased bowel activity, particularly in patients with risk factors for gastrointestinal obstruction or following recent abdominal surgery. In patients with preexisting constipation receiving subcutaneous granisetron, consider optimizing bowel regimens.

The terbutaline in Bricanyl has a moderate potential interaction with Heart Disease.

Adrenergic bronchodilators can stimulate cardiovascular beta- 1 and beta- 2 receptors, resulting in adverse effects such as tachycardia, palpitation, peripheral vasodilation, blood pressure changes, and ECG changes (e.g., flattening of the T wave; prolongation of the QT interval; ST segment depression). Direct stimulation of cardiac tissues is mediated by beta- 1 receptors and thus less likely to occur with beta-2-selective agents such as albuterol. However, beta-2-selectivity is not absolute and can be lost with larger doses. High dosages of these agents have been associated with precipitation or aggravation of angina, myocardial ischemia, and cardiac arrhythmias. Therapy with adrenergic bronchodilators should be administered cautiously in patients with sensitivity to sympathomimetic amines, hyperthyroidism, and/or underlying cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, or hypertension. The recommended dosages should not be exceeded.

The terbutaline in Bricanyl has a moderate potential interaction with High Blood Pressure.

Adrenergic bronchodilators can stimulate cardiovascular beta- 1 and beta- 2 receptors, resulting in adverse effects such as tachycardia, palpitation, peripheral vasodilation, blood pressure changes, and ECG changes (e.g., flattening of the T wave; prolongation of the QT interval; ST segment depression). Direct stimulation of cardiac tissues is mediated by beta- 1 receptors and thus less likely to occur with beta-2-selective agents such as albuterol. However, beta-2-selectivity is not absolute and can be lost with larger doses. High dosages of these agents have been associated with precipitation or aggravation of angina, myocardial ischemia, and cardiac arrhythmias. Therapy with adrenergic bronchodilators should be administered cautiously in patients with sensitivity to sympathomimetic amines, hyperthyroidism, and/or underlying cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, or hypertension. The recommended dosages should not be exceeded.

The terbutaline in Bricanyl has a moderate potential interaction with Hyperthyroidism.

Adrenergic bronchodilators can stimulate cardiovascular beta- 1 and beta- 2 receptors, resulting in adverse effects such as tachycardia, palpitation, peripheral vasodilation, blood pressure changes, and ECG changes (e.g., flattening of the T wave; prolongation of the QT interval; ST segment depression). Direct stimulation of cardiac tissues is mediated by beta- 1 receptors and thus less likely to occur with beta-2-selective agents such as albuterol. However, beta-2-selectivity is not absolute and can be lost with larger doses. High dosages of these agents have been associated with precipitation or aggravation of angina, myocardial ischemia, and cardiac arrhythmias. Therapy with adrenergic bronchodilators should be administered cautiously in patients with sensitivity to sympathomimetic amines, hyperthyroidism, and/or underlying cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, or hypertension. The recommended dosages should not be exceeded.

The terbutaline in Bricanyl has a moderate potential interaction with Hypokalemia.

Adrenergic bronchodilators may cause decreases in serum potassium concentrations, primarily when given by nebulization or intravenous administration. Although this effect is usually transient and does not require supplementation, clinically significant hypokalemia may occur in some patients, with the potential to induce cardiovascular adverse effects. The relevance of these observations to oral or oral aerosol/powder for inhalation therapy is unknown. Therapy with adrenergic bronchodilators should be administered cautiously in patients with or predisposed to hypokalemia.

Granisetron has a moderate potential interaction with Neutropenia.

Serious or severe injection site reactions have been reported with the subcutaneous formulation of granisetron. Patients who are neutropenic may be at greater risk; monitor for injection site reactions during treatment and consider discontinuing therapy for severe or persistent reactions.

Granisetron has a moderate potential interaction with Renal Dysfunction.

The subcutaneous formulation of granisetron should be avoided in patients with severe renal dysfunction. In patients with moderate renal dysfunction, subcutaneous granisetron should not be administered more frequently than once every 14 days because the clinical significance of potential prolonged elimination of the polymer vehicle is unknown.

The terbutaline in Bricanyl has a moderate potential interaction with Seizures.

Adrenergic bronchodilators may cause CNS stimulation. Therapy with adrenergic bronchodilators should be administered cautiously in patients with seizure disorders. Systemic adverse effects are minimized, but not abolished, by administration of these agents via oral inhalation.